Vice President, Obesity Strategy

Pfizer•New York, NY

5d•Hybrid

About The Position

We are seeking a senior enterprise executive and strategic architect to join our team as Vice President, Obesity Strategy, reporting directly to the Obesity Franchise Development Head and operating as a core member of the obesity franchise senior leadership team. This role will serve as the enterprise‑wide executive accountable for leading the development and execution of Pfizer’s global obesity strategy across all key geographies, including the U.S. and China. The Vice President will hold end‑to‑end strategic and financial ownership for the obesity franchise, setting long‑term direction, defining strategic choices, and driving enterprise‑level alignment and decisive execution across R&D, Commercial, Medical, Development, Finance, and other critical functions. The ideal candidate will bring recognized executive leadership credibility, a deep command of the evolving obesity ecosystem, and the organizational authority and influence required to shape portfolio strategy, capital allocation, and long‑term enterprise value creation. This role requires a seasoned executive leader who can operate with autonomy at the most senior levels of Pfizer, seamlessly integrate scientific rigor with commercial and financial strategy, own and drive high‑stakes enterprise decisions in a complex global matrix, and represent the obesity franchise internally and externally as a thought leader and strategic voice.

Requirements

MD/PhD or PhD with deep domain expertise in obesity, endocrinology, or related metabolic diseases.
12–15+ years of experience in the pharmaceutical or biotechnology industry, including senior leadership roles with enterprise‑level accountability in a large, complex global organization.
Proven experience shaping and leading global franchise or portfolio strategy, including investment prioritization, lifecycle planning, and cross‑functional execution.
Recognized expertise in the obesity and metabolic disease landscape, spanning scientific innovation, clinical development, commercial strategy, and evolving healthcare economics.
Demonstrated ability to influence and drive decisions at the Executive Leadership Team level, lead enterprise initiatives with material financial impact, and operate effectively in high‑ambiguity, high‑stakes environments.
Ability to architect and lead long‑term, enterprise strategies that integrate science, business, and financial value creation.
Strong executive presence, judgment, and credibility, with the ability to challenge, align, and influence the most senior leaders across Pfizer.
Comfort driving clear decisions and accountability in a complex, global matrix, balancing collaboration with decisive leadership.
Ability to anticipate shifts in science, market dynamics, and policy, recalibrating strategy proactively to sustain long‑term franchise leadership.
Permanent work authorization in the United States.

Nice To Haves

Prior experience with a top‑tier management consulting firm or equivalent enterprise strategy leadership experience highly desirable.

Responsibilities

Define and own the long‑term, enterprise obesity strategy, establishing the strategic ambition, success metrics, and roadmap to deliver sustained scientific leadership, competitive differentiation, and franchise growth.
Serve as the primary executive decision owner for obesity‑related strategic choices across the enterprise. Lead and chair, as appropriate, senior‑level governance, prioritization, and investment forums, driving alignment across R&D, Commercial, Medical, and Development. Act as a trusted strategic advisor to the Obesity Franchise Development Head and Pfizer senior leadership on high‑impact decisions.
Own portfolio‑level trade‑offs and capital allocation decisions, shaping investment strategy across the obesity pipeline and lifecycle. Drive enterprise financial accountability, scenario planning, and value maximization, with clear linkage between scientific strategy, commercial outcomes, and shareholder value.
Serve as Pfizer’s executive authority on obesity strategy, delivering forward‑looking insights on scientific innovation, competitive dynamics, payer and policy evolution, and market outlook. Represent the franchise with external stakeholders as appropriate, including scientific leaders, key partners, and industry forums.
Set the scientific and innovation agenda for obesity in partnership with R&D leadership, ensuring alignment between emerging biology, translational opportunities, and portfolio strategy. Provide executive‑level guidance on risk‑taking, innovation priorities, and platform evolution.
Lead with enterprise mindset and executive authority in a highly matrixed global organization, holding senior leaders accountable for outcomes rather than consensus alone. Build and sustain senior‑level coalitions, influence across reporting lines, and drive outcomes even in the absence of direct people management authority.